With ASCO data tallied, Bristol-Myers loses ground to Merck in I-O field

7th June 2017 Uncategorised 0

Thanks to a raft of promising Keytruda results—in tandem with Incyte’s epacadostat, in certain high-risk breast cancers and in combination with chemo in lung cancer—industry watchers crowned Merck the immuno-oncology field’s weekend victor against rival Bristol-Myers Squibb.

More: With ASCO data tallied, Bristol-Myers loses ground to Merck in I-O field
Source: fierce